$298.55+0.65 (+0.22%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Krystal Biotech (KRYS) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~177.0%/yr (FY23→FY25), net margin 52.6%, and free cash flow (~$188.9M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+34.9%) and Capex step-up ($12.0M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲33.9%
389.1
FY21→FY25CAGR —
Net income ($M)▲129.7%
204.8
one-off year: see footnoteCAGR —
Free cash flow ($M)▲58.5%
188.9
capex stepped upCAGR —
Diluted EPS▲128.0%
6.84
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+34.9%
22.2mn → 30.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$12.0M
▲182% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
53¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Net margin 52.6% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 470.0 | 389.1 | 290.5 | 50.7 | 0.0 | 0.0 | ▲33.9% | — |
Cost of revenue | 26.9 | 23.0 | 20.1 | 3.1 | 0.0 | 0.0 | ▲14.9% | — |
Gross profit | 443.1 | 366.1 | 270.5 | 47.6 | 0.0 | 0.0 | ▲35.4% | — |
Research & development | 59.5 | 58.0 | 53.6 | 46.4 | 42.5 | 27.9 | ▲8.3% | +20.1% |
Selling, general & admin | 156.1 | 146.7 | 113.6 | 98.3 | 77.7 | 40.4 | ▲29.1% | +38.1% |
Total operating expenses | 215.6 | 204.8 | 204.7 | 157.2 | 145.2 | 68.3 | ▲0.0% | +31.6% |
Operating incomefeeds ROC rank | 227.5 | 161.3 | 65.7 | −109.6 | −145.2 | −68.3 | ▲145.3% | — |
Other income, net | 31.3 | 28.2 | 29.6 | 122.5 | 5.2 | −1.3 | — | — |
Pretax income | 258.8 | 189.5 | 95.4 | 12.9 | −140.0 | −69.6 | ▲98.7% | — |
Income tax | 33.6 | −15.4 | 6.2 | 2.0 | 0.0 | 0.0 | — | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 225.2 | 204.8 | 89.2 | 10.9 | −140.0 | −69.6 | ▲129.7% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 7.36 | 6.84 | 3.00 | 0.39 | −5.49 | −3.13 | ▲128.0% | — |
Diluted shares (mn) | 30.84 | 29.95 | 29.74 | 27.75 | 25.49 | 22.20 | ▲0.7% | +7.8% |
| Margins | ||||||||
Gross margin91st pct in Healthcare | 94.3% | 94.1% | 93.1% | 93.9% | — | — | ▲1.0pp | +0.2pp |
Operating margin | 48.4% | 41.5% | 22.6% | −216.2% | — | — | ▲18.8pp | +257.7pp |
Net margin99th pct in Healthcare | 47.9% | 52.6% | 30.7% | 21.6% | — | — | ▲21.9pp | +31.1pp |
† TTM = trailing four quarters through 2026-09-30.FY23 effective tax rate was 15% vs a 0% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was −8% vs a 0% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Krystal Biotech's revenue last fiscal year?
Krystal Biotech reported revenue of $389.1M in fiscal 2025, up 33.9% from fiscal 2024.
What was Krystal Biotech's net income?
Krystal Biotech reported net income of $204.8M in fiscal 2025, a net margin of 52.6%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

